1992
Fulminant Epstein‐Barr virus‐associated post‐transplant lymphoproliferative disorders following OKT3 therapy
Canfield C, Hudnall S, Colonna J, Busuttil R, Wilkinson A, Danovitch G, Shaked A, Goldstein L, Rosenthal J. Fulminant Epstein‐Barr virus‐associated post‐transplant lymphoproliferative disorders following OKT3 therapy. Clinical Transplantation 1992, 6: 1-9. DOI: 10.1111/j.1399-0012.1992.tb00580.x.Peer-Reviewed Original ResearchPost-transplant lymphoproliferative disorderLymphoproliferative disordersEpstein-Barr virus-associated post-transplant lymphoproliferative disorderAssociated with Epstein-Barr virusOKT3 monoclonal antibody therapySequelae of immunosuppressionWithdrawal of immunosuppressionMonoclonal antibody therapyPeripheral blood smearEpstein-Barr virusOKT3 therapyAtypical lymphocytesMalignant lymphomaAntibody therapyClinical spectrumProphylactic useImmunosuppressionOKT3Medical CenterBlood smearsAcyclovirTherapyDisordersLymphomaLymphocytes
1991
Cyclosporin A renders target cells resistant to immune cytolysis
Hudnall S. Cyclosporin A renders target cells resistant to immune cytolysis. European Journal Of Immunology 1991, 21: 221-226. PMID: 1846819, DOI: 10.1002/eji.1830210133.Peer-Reviewed Original ResearchConceptsCsA dose reductionB-cell hyperplasiaB lymphocytesDose reductionCell growth inhibitionNatural killerCell hyperplasiaEarly post-transplant lymphoproliferative disordersHuman organ transplant recipientsPost-transplant lymphoproliferative disorderT cell-dependent responsesAntibody-dependent responsesPost-transplant settingOrgan transplant recipientsTarget cellsEpstein-Barr virusCell-dependent responsesHuman target cellsComplement-mediated cytolysisGrowth inhibitionTransplant recipientsDisease regressionImmune controlNK cellsLymphoproliferative disorders